Table 1 Demographic and clinical characteristics of the series
From: Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
Variables | Cases (TNS ≥ 15; n = 46) N (%) | Controls (TNS ≤ 6; n = 48) N (%) | P value* |
|---|---|---|---|
Sex | ns | ||
Female | 14 (30%) | 16 (33%) | |
Male | 32 (70%) | 32 (67%) | |
Age | ns | ||
Median (min-max) | 65 (41–83) | 66 (36–82) | |
Diabetes | 0.0055 | ||
Yes | 11 (24%) | 2 (4%) | |
No | 35 (76%) | 46 (96%) | |
Hypothyroidism | ns | ||
Yes | 0 (0%) | 0 (0%) | |
No | 46 (100%) | 48 (100%) | |
Tumor location | ns | ||
Colon | 23 (50%) | 30 (63%) | |
Rectum | 9 (20%) | 7 (15%) | |
Biliary duct | 2 (4%) | 2 (4%) | |
Pancreas | 3 (6%) | 4 (8%) | |
Stomach | 9 (20%) | 5 (10%) | |
Type of chemotherapy | ns | ||
XELOX | 35 (76%) | 29 (61%) | |
-Adjuvant | 25 | 20 | |
-Palliative | 10 | 9 | |
FOLFOX | 6 (13%) | 11 (23%) | |
-Adjuvant | 3 | 8 | |
-Palliative | 3 | 3 | |
TOMOX | 0 (0%) | 2 (4%) | |
-Adjuvant | 0 | 0 | |
-Palliative | 0 | 2 | |
FOLFIRINOX | 1 (2%) | 2 (4%) | |
-Palliative | 1 | 2 | |
EOX | 4 (9%) | 4 (8%) | |
-Perioperative | 4 | 4 | |
-Palliative | 0 | 0 | |
Stage AJCC | ns | ||
I-II | 18 (39%) | 16 (33%) | |
III-IV | 28 (61%) | 32 (67%) | |
Cumulative dose of oxaliplatin (mg) | ns | ||
Median (min-max) | 1616 (880–2045) | 1624 (900–2050) |